-
CompareHUVEC – Human Umbilical Vein Endothelial Cells, Single Donor, in EGM™-2Catalog #: C2517A
Cryopreserved ampule of Human Umbilical Vein Endothelial Cells (HUVEC), from a single donor, in EGMTM-2 containing ≥ 500,000 cells
Sales unit: each -
CompareMsGM™ Mesangial Cell Growth Medium SingleQuots™ Supplements and Growth FactorsCatalog #: CC-4146MsGMTM Mesangial SingleQuotsTM KitSales unit: each
-
CompareP5 Primary Cell 4D-Nucleofector™ X Kit LCatalog #: V4XP-5024For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-NucleofectorTM X Unit (100 µL format).Sales unit: kit
-
CompareP5 Primary Cell 4D-Nucleofector™ X Kit LCatalog #: V4XP-5012For efficient transfection of specific primary cells, e.g. HUVEC, in the 4D-NucleofectorTM X Unit (100 µL format).Sales unit: kit
-
CompareP2 Primary Cell 4D-Nucleofector™ X Kit LCatalog #: V4XP-2024
For efficient transfection of specific primary cells, e.g. mouse macrophages and NHDF, in the 4D-NucleofectorTM X Unit (100 µL format).
Sales unit: kit -
CompareP2 Primary Cell 4D-Nucleofector™ X Kit LCatalog #: V4XP-2012
For efficient transfection of specific primary cells, e.g. mouse macrophages and NHDF, in the 4D-NucleofectorTM X Unit (100 µL format).
Sales unit: kit -
ComparePyroCell® Monocyte Activation Test – Human Serum SystemCatalog #: 00279791
The PyroCell® Monocyte Activation Test – Human Serum System (PyroCell® MAT HS System) is an all-inclusive kit to conduct the Monocyte Activation Test. It contains 3 vials of cryopreserved, pooled PBMC (human, pMAT Cells), 3 vials Human Serum Supplement, the PeliKine compact human IL-6 kit and the PeliKine tool set, for 288 test (3x 96-well microtiter plates).
Sales unit: kit -
CompareProCHO® 4 Protein-free CHO Medium, 1LCatalog #: BEBP12-029Q
ProCHO® 4 Protein-free CHO Medium with 0.1% Pluronic® F-68 and phenol red, without L-Glutamin, hypoxanthine or thymidine, 1 L
Sales unit: each -
CompareProCHO® 5 Protein-free CHO Medium Powder kit, 500 LCatalog #: BE15-766LProCHO® 5 Protein-free CHO Medium Powder kit with HEPES and 0.1% Pluronic® F-68, without L-Glutamine, phenol red, hypoxanthine or thymidine, 500 L (NAO)
Sales unit: kit -
CompareREGMTM Renal Epithelial Cell Growth Medium SingleQuotsTM KitCatalog #: CC-4127Supplements and growth factors required for culture of Renal Epithelial Cells (basal media sold separately)Sales unit: each
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay -
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.